Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
PolyPid ( (PYPD) ) just unveiled an announcement.
PolyPid Ltd., an Israeli company, has released its unaudited interim condensed consolidated financial statements for the six months ending June 30, 2025. The report highlights an increase in total assets from $25.2 million at the end of 2024 to $37.7 million by mid-2025, driven by a rise in cash and cash equivalents and short-term deposits. Despite this growth, the company reported an operating loss, attributed to increased research and development expenses. This financial update provides stakeholders with insights into the company’s financial health and its ongoing investments in research and development.
The most recent analyst rating on (PYPD) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on PolyPid stock, see the PYPD Stock Forecast page.
Spark’s Take on PYPD Stock
According to Spark, TipRanks’ AI Analyst, PYPD is a Neutral.
PolyPid’s score reflects significant financial challenges, including consistent losses and negative equity. While the company’s clinical advancements and financing efforts are promising, they are not sufficient to offset the financial risks. The stock exhibits neutral technical indicators and an unattractive valuation, limiting its appeal to investors.
To see Spark’s full report on PYPD stock, click here.
More about PolyPid
Average Trading Volume: 517,084
Technical Sentiment Signal: Sell
Current Market Cap: $34.85M
Learn more about PYPD stock on TipRanks’ Stock Analysis page.